Search

Sustaining Advocacy

EXPrESSIVE Phase III Program Countries of MK-8527

Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.

Getting LEN Rollout Right

Advancing Research, Redefining Choice

Protecting Global Prevention Gains

The Fight to Save HIV Research

AVAC Year in Review

Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of February 2026.

CROI 2026: Resources and what to watch

AVAC will be tracking the HIV and STI science at CROI 2026, including advances in long-acting HIV prevention, evolving science around cure, and important discussions on the impact of the global funding crisis on research, development, and delivery. Here we share ways to follow and join in the conversation, in-person or virtually. 

AVAC Infographics for CROI 2026

Going to CROI? AVAC’s up-to-date infographics — on the research & development pipeline, prevention options, and the impact of US funding cuts — are available here for use in conference presentations. We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.